Dr.Kuldeep Singh (Diplomate ACVP) currently serve as a Director of Pathology at WuXi AppTec Inc He has over 10 years of experience in anatomic pathology Prior to joining WuXi AppTec Inc he worked at Sanofi as a Senior and Principal Scientist He has also held position at University of Illinois as a Clinical Assistant and Associate Professor, and Head of Anatomic Pathology. He completed his PhD and residency in anatomic pathology at Oklahoma State University, MS at University of Utrecht, and BVSc at G B Pant University of Agriculture and Technology, Pantnagar His PhD was focused on molecular pathology and MS on experimental pathology. He has experience in investigative, toxicologic, and diagnostic pathology His experience in investigative pathology include working on studies aimed at target identification, target validation, lead candidate optimization, efficacy assessment, model characterization, and biomarker identification. His experience in toxicologic pathology include conducting preclinical safety assessment of both small and large molecules intended for several therapeutic areas including oncology, immunology, rare diseases, and neuroscience. His areas of interests are investigative pathology, toxicologic pathology, digital pathology, biomarker identification, investigative toxicology, neuropathology, and immune system pathology.

Click here to register

--------------------------------------------------------------

Dr. Bhanu Singh is currently working as Senior Director, Pathology, at Gilead Sciences. Bhanu is a board certified veterinary anatomic pathologist (DACVP) and toxicologist (DABT) and is also a Fellow of International Academy of Toxicologic Pathology (IATP). He has over ten years of industry experience, most recently as Scientific Director, Pathology at Janssen Pharmaceuticals supporting discovery and nonclinical safety of Oncology and Cardiovascular & Metabolic Diseases programs. Dr. Singh has a strong scientific interest in drug discovery (oncology and cardiovascular metabolism), molecular pathology, liver toxicity, development of animal models of human diseases, and chemical carcinogenesis. He has authored over 20 peer-reviewed publications, five book chapters, and 80+ regulatory and research pathology reports and delivered more than 70 presentations in various scientific meetings. Dr. Singh is actively involved in professional activities for various societies of toxicology and pathology, such as Chair for the STP education course committee, and in the past has served as Associate Editor for Drug and Chemical Toxicology, Chair for the IFSTP-IATP webinar committee, and Chair for Dog INHAND committee. Dr. Singh completed his pathology residency training at the Royal Veterinary College, London (United Kingdom). During his residency training, he did internships and externships at Bern University (Switzerland); the University of California, Davis (United States); the Armed Force Institute of Pathology (Washington, DC); and the National Institute of Environmental Health Sciences (NIEHS). After finishing his residency, he worked at NIEHS/NTP (Research Triangle Park, North Carolina) as a Visiting Fellow in Dr. Dave Malarkey’s laboratory. He received his veterinary training at G. B. Pant University (Pantnagar, India) and a masters at Utrecht University (Netherlands).  

--------------------------------------------------------------

Dr.Ester Lovsin Barle (DVM, MScTox, PhD) is the Head of Product Stewardship & Health at Takeda, Switzerland. Her responsibilities include scientific development and cross-organizational implementation of health based exposure limits (HBEL), compiling global policy on occupational toxicology and patient safety related process in support of manufacturing globally, as well as global implementation of safe handling of chemicals.  

Dr. Vijayapal Reddy (DVM, PhD, DABT) is Director at Vipra LLC, USA. He has over 30 years of experience in global pharmaceutical drug discovery. He worked as an ICH S9 Expert Working Group (EWG) member for developing anticancer pharmaceuticals.  

---------------------------------------------------------------

Dr. Sol Bobst (MBA, PhD, DABT) has over 15 years of professional experience. He is the founder, President, and Principal Advisors of ToxSci Advisors LLC.  Ms. Gowri Sukumar (MS, RAC) is the Director, CMC and Regulatory Affairs for Iterion Therapeutics. She has broad responsibilities that include process development, Drug Substance and Drug Product manufacturing from the CMC side. From the Regulatory affairs perspective, she provides regulatory leadership and expertise for regulatory strategy, liaises with the regulatory agencies including FDA, Health Canada and other Health authorities.